Market Access How cost and perception could reshape the GLP-1 market BioPharma DiveAs Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.Metabolic & GLP-1Read full story pharminent August 21, 2026 (Last updated: August 23, 2026) BioPharma Dive As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners. Metabolic & GLP-1 Read full story Post navigation Previous: Regeneron’s Pasatru Wins Full FDA Approval for Ultra-Rare ‘Stone Man Disease’Next: Novo Nordisk starts trialing lower maintenance doses of oral Wegovy Related Stories Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026 Market Access UK, pharma industry pilot rapid access routes for medicines pharminent July 5, 2026
